Baur and colleagues reanalyzed the study, which included 255 adults (155 women) who had either received a weekly treatment of 1.5 mg dulaglutide or placebo — in addition to standard smoking ...

This trial compared once-weekly dulaglutide, a GLP-1 receptor agonist, with placebo for glycemic control in youths with type 2 diabetes who may have been receiving metformin or basal insulin.

The researchers found that at week 40, the change from baseline in HbA1c was −1.44 and −0.67% with tirzepatide and dulaglutide escalation to 4.5mg or maximum tolerated dose, respectively.

SURPASS-CVOT evaluated the efficacy and safety of tirzepatide compared with dulaglutide in adults with T2D and a confirmed ASCVD.